This immunocytokine selectively targets tumor-infiltrating PD-1+CD8+ T cells, enhancing its bioactivity via anti-PD-1-mediated cis-binding of IL-12 mutant, with a mechanism involving IFN-γ.63 Here, IFNG is linked to neoplasm.